Soochow Securities·2025-05-05 15:25Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company achieved significant revenue growth in 2024, with total revenue reaching 27.21 billion yuan, a year-on-year increase of 56.19%. The net profit attributable to shareholders was a loss of 4.98 billion yuan, but the company is expected to turn positive in GAAP operating profit in 2025 [8] - The global sales of the core product, Zebutinib, have rapidly increased, with 2024 global sales reaching 2.6 billion USD, a year-on-year growth of 105%. The company is positioned as a leader in the hematological malignancies sector [8] - The company is advancing its pipeline for solid tumors, with 13 innovative molecules entering clinical development in 2024, focusing on lung cancer, breast cancer, and gastrointestinal tumors [8] Financial Projections - Total revenue projections for the company are as follows: 35.86 billion yuan in 2025, 43.74 billion yuan in 2026, and 53.37 billion yuan in 2027, with respective year-on-year growth rates of 31.75%, 22.00%, and 22.00% [1][9] - The net profit attributable to shareholders is projected to be 403.5 million yuan in 2025, 3.59 billion yuan in 2026, and 6.75 billion yuan in 2027, with significant growth rates of 108.11% and 790.43% in the following years [1][9] - The earnings per share (EPS) is expected to turn positive in 2025 at 0.29 yuan, increasing to 2.56 yuan in 2026 and 4.82 yuan in 2027 [1][9] Market Data - The closing price of the company's stock is 261.18 yuan, with a market capitalization of approximately 365.98 billion yuan [5] - The company has a price-to-book ratio of 14.99 and a total circulating A-share market value of 30.05 billion yuan [5][6]